Witnessing the stock’s movement on the chart, on Wednesday, Immunocore Holdings plc ADR (NASDAQ: IMCR) had a quiet start as it plunged -3.88% to $28.26, before settling in for the price of $29.40 at the close. Taking a more long-term approach, IMCR posted a 52-week range of $28.17-$76.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 88.61% over the last 5 years. Nevertheless, stock’s Earnings Per Share (EPS) this year is 25.30%. This publicly-traded company’s shares outstanding now amounts to $50.03 million, simultaneously with a float of $48.66 million. The organization now has a market capitalization sitting at $1.41 billion. At the time of writing, stock’s 50-day Moving Average stood at $32.13, while the 200-day Moving Average is $41.95.
Immunocore Holdings plc ADR (IMCR) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Immunocore Holdings plc ADR’s current insider ownership accounts for 2.74%, in contrast to 87.82% institutional ownership. According to the most recent insider trade that took place on Apr 01 ’24, this organization’s CHIEF HR OFFICER sold 4,375 shares at the rate of 64.06, making the entire transaction reach 280,262 in total value, affecting insider ownership by 0. Preceding that transaction, on Feb 28 ’24, Company’s HEAD OF R&D sold 36,509 for 68.59, making the whole transaction’s value amount to 2,504,158. This particular insider is now the holder of 0 in total.
Immunocore Holdings plc ADR (IMCR) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
Immunocore Holdings plc ADR’s EPS increase for this current 12-month fiscal period is 25.30% and is forecasted to reach -1.40 in the upcoming year.
Immunocore Holdings plc ADR (NASDAQ: IMCR) Trading Performance Indicators
Let’s observe the current performance indicators for Immunocore Holdings plc ADR (IMCR). It’s Quick Ratio in the last reported quarter now stands at 3.76. The Stock has managed to achieve an average true range (ATR) of 1.55. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.75. Similarly, its price to free cash flow for trailing twelve months is now 67.45.
In the same vein, IMCR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.96, a figure that is expected to reach -0.23 in the next quarter, and analysts are predicting that it will be -1.40 at the market close of one year from today.
Technical Analysis of Immunocore Holdings plc ADR (IMCR)
Going through the that latest performance of [Immunocore Holdings plc ADR, IMCR]. Its last 5-days volume of 0.49 million was inferior to the volume of 0.5 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 20.87% While, its Average True Range was 1.55.
Raw Stochastic average of Immunocore Holdings plc ADR (IMCR) in the period of the previous 100 days is set at 3.16%, which indicates a major fall in contrast to 7.31% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 29.88% that was lower than 37.18% volatility it exhibited in the past 100-days period.
